Humana (HUM) EBITDA (2009 - 2026)

Humana (HUM) has 18 years of EBITDA data on file, last reported at $1.8 billion in Q1 2026.

• On a quarterly basis, EBITDA fell 12.91% year-over-year to $1.8 billion in Q1 2026; TTM through Mar 2026 was $2.4 billion, a 26.83% decrease from a year earlier, with the FY2025 full-year figure at $2.7 billion, up 5.54% from the prior year.
• EBITDA for Q1 2026 stood at $1.8 billion, up from -$808.0 million in the prior quarter.
• Over the last five years, EBITDA for HUM reached as high as $2.0 billion in Q1 2025 and fell as low as -$808.0 million in Q4 2025.
• Historically, EBITDA has averaged $872.5 million across 5 years, with a median of $1.2 billion in 2022.
• Across the five-year window, EBITDA jumped 3651.52% in 2022 and tumbled 380.65% in 2023, its largest moves.
• Year by year, EBITDA stood at $124.0 million in 2022, then tumbled by 380.65% to -$348.0 million in 2023, then plunged by 56.03% to -$543.0 million in 2024, then tumbled by 48.8% to -$808.0 million in 2025, then soared by 317.08% to $1.8 billion in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $1.8 billion in Q1 2026, -$808.0 million in Q4 2025, and $400.0 million in Q3 2025.